SAN DIEGO--(BUSINESS WIRE)--Aethlon Medical, Inc. (OTCBB:AEMD) disclosed today it has submitted a Phase I Small Business Innovation Research (SBIR) grant to the National Institutes of Health (NIH) entitled, “Affinity Capture of Low Abundance Prostate Cancer Biomarkers From Sera.” The submission proposes to investigate the utility of the Aethlon Hemopurifier® to rapidly isolate and identify prostate cancer biomarkers from the blood. The submission is the third in a series of cancer-related grants recently submitted by Aethlon Medical. The Company anticipates further submissions prior to year-end.
